International Journal of Hematology

, Volume 79, Issue 1, pp 63–73 | Cite as

The Protein Tyrosine Phosphatase CD45 Is Required for Interleukin 6 Signaling in U266 Myeloma Cells

  • Qun Zhou
  • Yuan Yao
  • Solveig G. Ericson
Case Report


The objective of this study was to examine whether CD45 mediates interleukin 6 (IL-6) signaling in human multiple myeloma (MM) cells. We chose U266 MM cells as a study model and isolated cells into CD45+ and CD45- subpopulations. CD45+ and CD45- U266 cells were cocultured with bone marrow stromal cells (BMSCs). IL-6-induced proliferation in CD45+ U266 cells was inhibited by vanadate, a potent protein tyrosine phosphatase inhibitor. However, IL-6-independent CD45- U266 cell growth was not affected by vanadate. CD45+ U266 cells, but not CD45- U266 cells, have the capability of cell adhesion concomitant with actin filament polymerization at the adherent cells. Adhesion of CD45+ U266 cells to BMSCs was impaired by vanadate. We clarified the signaling differences between CD45+ and CD45- U266 cells in response to IL-6. In CD45+ U266 cells, IL-6 increased tyrosine phosphorylation of gp130 and STAT3 and stimulated the level of Mcl-1 protein expression. An association between CD45 and the Src-family protein tyrosine kinase, Lyn, was maintained in the presence of IL-6; the formation of the CD45/Lyn complex was impaired by vanadate. Additionally, IL-6-induced Lyn kinase activity in CD45+ U266 cells was increased by the cross-linking of CD45, and this increase was due to the dephosphorylation of Tyr507 at Lyn. In conclusion, IL-6-dependent MM cells require CD45 to initiate IL-6 signaling and to maintain Lyn kinase activity, both of which are essential for cell proliferation and cell adhesion.

Key words

CD45 IL-6-dependent/independent myeloma cells Lyn kinase 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.Blood. 1989;73:517–526.PubMedGoogle Scholar
  2. 2.
    Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process.Blood. 1998;91:3–21.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Thomas X, Anglaret B, Magaud JP, Epstein J, Archimbaud E. Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma.Leuk Lymphoma. 1998;32:107–119.CrossRefPubMedGoogle Scholar
  4. 4.
    Schwab G, Siegall CB, Aarden LA, Neckers LM, Nordan RP. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266.Blood. 1991;77:587–593.PubMedGoogle Scholar
  5. 5.
    Bisping G, Leo R, Wenning D, et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma.Blood. 2003;101:2775–2783.CrossRefPubMedGoogle Scholar
  6. 6.
    Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130.Blood. 1995;86:1243–1254.PubMedGoogle Scholar
  7. 7.
    Hallek M, Neumann C, Schaffer M, et al. Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines.Exp Hematol. 1997;25:1367–1377.PubMedGoogle Scholar
  8. 8.
    Ogata A, Chauhan D, Teoh G, et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade.J Immunol. 1997;159:2212–2221.PubMedGoogle Scholar
  9. 9.
    Schwarze MM, Hawley RG. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL.Cancer Res. 1995;55:2262–2265.PubMedGoogle Scholar
  10. 10.
    Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway.Eur J Immunol. 1999;29:3945–3950.CrossRefPubMedGoogle Scholar
  11. 11.
    Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival.Science. 1998;281:1322–1326.CrossRefPubMedGoogle Scholar
  12. 12.
    Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.Blood. 2002;100:194–199.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma.Blood. 2002;99:1885–1893.CrossRefPubMedGoogle Scholar
  14. 14.
    Brown VK, Ogle EW, Burkhardt AL, Rowley RB, Bolen JB, Justement LB. Multiple components of the B-cell antigen receptor complex associate with the protein tyrosine phosphatase, CD45.J Biol Chem. 1994;269:17238–17244.PubMedGoogle Scholar
  15. 15.
    Irie-Sasaki J, Sasaki T, Matsumoto W, et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling.Nature. 2001;409:349–354.CrossRefPubMedGoogle Scholar
  16. 16.
    Thomas ML, Brown EJ. Positive and negative regulation of Src- family membrane kinases by CD45.Immunol Today. 1999;20:406–411.CrossRefPubMedGoogle Scholar
  17. 17.
    Blank N, Kriegel M, Hieronymus T, et al. CD45 tyrosine phosphatase controls common gamma-chain cytokine-mediated STAT and extracellular signal-related kinase phosphorylation in activated human lymphoblasts: inhibition of proliferation without induction of apoptosis.J Immunol. 2001;166:6034–6040.CrossRefPubMedGoogle Scholar
  18. 18.
    Yanagi S, Sugawara H, Kurosaki M, Sabe H, Yamamura H, Kurosaki T. CD45 modulates phosphorylation of both autophosphorylation and negative regulatory tyrosines of Lyn in B-cells.J Biol Chem. 1996;271:30487–30492.CrossRefPubMedGoogle Scholar
  19. 19.
    D’Oro U, Ashwell JD. Cutting edge: the CD45 tyrosine phosphatase is an inhibitor of Lck activity in thymocytes.J Immunol. 1999;162:1879–1883.PubMedGoogle Scholar
  20. 20.
    Trowbridge IS, Thomas ML. CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development.Annu Rev Immunol. 1994;12:85–116.CrossRefPubMedGoogle Scholar
  21. 21.
    Greer SF, Lin J, Clarke CH, Justement LB. Major histocompatibility class II-mediated signal transduction is regulated by the proteintyrosine phosphatase CD45.J Biol Chem. 1998;273:11970–11979.CrossRefPubMedGoogle Scholar
  22. 22.
    Pao LI, Cambier JC. Syk, but not Lyn, recruitment to B-cell antigen receptor and activation following stimulation of CD45- B-cells.J Immunol. 1997;158:2663–2669.PubMedGoogle Scholar
  23. 23.
    Ishikawa H, Tsuyama N, Abroun S, et al. Requirements of src family kinase activity associated with CD45 for myeloma cell proliferation by interleukin-6.Blood. 2002;99:2172–2178.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Mustelin T, Altman A. Dephosphorylation and activation of the T cell tyrosine kinase pp56lck by the leukocyte common antigen (CD45).Oncogene. 1990;5:809–813.PubMedGoogle Scholar
  25. 25.
    Justement LB. The role of CD45 in signal transduction.Adv Immunol. 1997;66:1–65.CrossRefPubMedGoogle Scholar
  26. 26.
    Jensen GS, Mant MJ, Belch AJ, Berenson JR, Ruether BA, Pilarski LM. Selective expression of CD45 isoforms defines CALLA+ monoclonal B-lineage cells in peripheral blood from myeloma patients as late stage B-cells.Blood. 1991;78:711–719.PubMedGoogle Scholar
  27. 27.
    Mahmoud MS, Ishikawa H, Fujii R, Kawano MM. Induction of CD45 expression and proliferation in U-266 myeloma cell line by interleukin-6.Blood. 1998;92:3887–3897.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Grigorieva I, Thomas X, Epstein J. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone.Exp Hematol. 1998;26:597–603.PubMedGoogle Scholar
  29. 29.
    Kawano MM, Ishikawa H, Tsuyama N, et al. Growth mechanism of human myeloma cells by interleukin-6.Int J Hematol. 2002;76(suppl 1):329–333.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Piccardoni P, Sideri R, Manarini S, et al. Platelet/polymorphonuclear leukocyte adhesion: a new role for SRC kinases in Mac-1 adhesive function triggered by P-selectin.Blood. 2001;98:108–116.CrossRefPubMedGoogle Scholar
  31. 31.
    Asosingh K, Menu E, Van Valckenborgh E, et al. Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma.Clin Exp Metastasis. 2002;19:583–591.CrossRefPubMedGoogle Scholar
  32. 32.
    Mudry RE, Fortney JE, York T, Hall BM, Gibson LF. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy.Blood. 2000;96:1926–1932.PubMedGoogle Scholar
  33. 33.
    Gao H, Henderson A, Flynn DC, Landreth KS, Ericson SG. Effects of the protein tyrosine phosphatase CD45 on FcγRIIa signaling and neutrophil function.Exp Hematol. 2000;28:1062–1070.CrossRefPubMedGoogle Scholar
  34. 34.
    Ericson SG, Zhao Y, Gao H, et al. Interleukin-6 production by human neutrophils after Fc-receptor cross-linking or exposure to granulocyte colony-stimulating factor.Blood. 1998;91:2099–2107.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Vanderkerken K, Asosingh K, Braet F, Van Riet I, Van Camp B. Insulin-like growth factor-1 acts as a chemoattractant factor for 5T2 multiple myeloma cells.Blood. 1999;93:235–241.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Frassanito MA, Cusmai A, Iodice G, Dammacco F. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis.Blood. 2001;97:483–489.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Okado T, Hawley RG. Adhesion molecules involved in the binding of murine myeloma cells to bone marrow stromal elements.Int J Cancer. 1995;63:823–830.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Darnell JE Jr. STATs and gene regulation.Science. 1997;277:1630–1635.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.Science. 1994;264:1415–1421.CrossRefPubMedGoogle Scholar
  40. 40.
    Shuai K, Schindler C, Prezioso VR, Darnell JE Jr. Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein.Science. 1992;258:1808–1812.CrossRefPubMedGoogle Scholar
  41. 41.
    Donella-Deana A, Cesaro L, Ruzzene M, Brunati AM, Marin O, Pinna LA. Spontaneous autophosphorylation of Lyn tyrosine kinase at both its activation segment and C-terminal tail confers altered substrate specificity.Biochemistry. 1998;37:1438–1446.CrossRefPubMedGoogle Scholar
  42. 42.
    Hata H, Matsuzaki H, Sonoki T, et al. Establishment of a CD45- positive immature plasma cell line from an aggressive multiple myeloma with high serum lactate dehydrogenase.Leukemia. 1994;8:1768–1773.PubMedGoogle Scholar
  43. 43.
    Ishikawa H, Mahmoud MS, Fujii R, Abroun S, Kawano MM. Proliferation of immature myeloma cells by interleukin-6 is associated with CD45 expression in human multiple myeloma.Leuk Lymphoma. 2000;39:51–55.CrossRefPubMedGoogle Scholar
  44. 44.
    Asosingh K,De Raeve H, Van Riet I, Van Camp B, Vanderkerken K. Multiple myeloma tumor progression in the 5T2 murine model is a multi-stage and dynamic process of differentiation, proliferation, invasion and apoptosis.Blood. 2003;101:3136–3141.CrossRefPubMedGoogle Scholar
  45. 45.
    Asosingh K, De Raeve H, Croucher P, et al. In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells.Exp Hematol. 2001;29:77–84.CrossRefPubMedGoogle Scholar
  46. 46.
    Shenoi H, Seavitt J, Zheleznyak A, Thomas ML, Brown EJ. Regulation of integrin-mediated T cell adhesion by the transmembrane protein tyrosine phosphatase CD45.J Immunol. 1999;162:7120–7127.PubMedGoogle Scholar
  47. 47.
    Spets H, Stromberg T, Georgii-Hemming P, Siljason J, Nilsson K, Jernberg-Wiklund H. Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6 (IL-6)-induced growth and survival.Eur J Haematol. 2002;69:76–89.CrossRefPubMedGoogle Scholar
  48. 48.
    Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells.Blood. 1993;81:3357–3364.PubMedGoogle Scholar
  49. 49.
    Ancey C, Kuster A, Haan S, Herrmann A, Heinrich PC, Muller-Newen G. A fusion protein of the gp130 and interleukin-6Rα ligand-binding domains acts as a potent interleukin-6 inhibitor.J Biol Chem. 2003;278:16968–16972.CrossRefPubMedGoogle Scholar
  50. 50.
    Rawat R, Rainey GJ,Thompson CD, Frazier-Jessen MR, Brown RT, Nordan RP. Constitutive activation of STAT3 is associated with the acquisition of an interleukin 6-independent phenotype by murine plasmacytomas and hybridomas.Blood. 2000;96:3514–3521.PubMedGoogle Scholar
  51. 51.
    Zhang B, Potyagaylo V, Fenton RG. IL-6-independent expression of Mcl-1 in human multiple myeloma.Oncogene. 2003;22:1848–1859.CrossRefPubMedGoogle Scholar
  52. 52.
    Puthier D,Thabard W, Rapp M, et al. Interferon alpha extends the survival of human myeloma cells through an upregulation of the Mcl-1 anti-apoptotic molecule.Br J Haematol. 2001;112:358–363.CrossRefPubMedGoogle Scholar
  53. 53.
    Chakraborty A, Tweardy DJ. Stat3 and G-CSF-induced myeloid differentiation.Leuk Lymphoma. 1998;30:433–442.CrossRefPubMedGoogle Scholar
  54. 54.
    Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer.Oncogene. 2000;19:5636–5642.CrossRefPubMedGoogle Scholar
  55. 55.
    Roach T, Slater S, Koval M, et al. CD45 regulates Src family member kinase activity associated with macrophage integrin-mediated adhesion.Curr Biol. 1997;7:408–417.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2004

Authors and Affiliations

  1. 1.Blood and Marrow Transplant and Hematologic Malignancy Program, Mary Babb Randolph Cancer CenterWest Virginia UniversityMorgantownUSA

Personalised recommendations